Form 8-K - Current report:
SEC Accession No. 0001999371-25-008877
Filing Date
2025-07-09
Accepted
2025-07-09 16:16:38
Documents
21
Period of Report
2025-07-09
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT tnxp-8k_070925.htm   iXBRL 8-K 28635
2 PRESS RELEASE ex99-01.htm EX-99.01 32968
3 PAIN RELIEF BY TARGETING NONRESTORATIVE SLEEP IN FIBROMYALGIA: A PHASE 3 RANDOMI ex99-02.htm EX-99.02 33210
7 GRAPHIC tonix_001.jpg GRAPHIC 5480
8 GRAPHIC ex99-02_001.jpg GRAPHIC 7532
9 GRAPHIC ex99-02_002.jpg GRAPHIC 81252
10 GRAPHIC ex99-02_003.jpg GRAPHIC 37551
11 GRAPHIC ex99-02_004.jpg GRAPHIC 42873
12 GRAPHIC ex99-02_005.jpg GRAPHIC 57561
13 GRAPHIC ex99-02_006.jpg GRAPHIC 53261
  Complete submission text file 0001999371-25-008877.txt   672096

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE tnxp-20250709.xsd EX-101.SCH 3023
5 XBRL LABEL FILE tnxp-20250709_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE tnxp-20250709_pre.xml EX-101.PRE 22364
23 EXTRACTED XBRL INSTANCE DOCUMENT tnxp-8k_070925_htm.xml XML 3543
Mailing Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928
Business Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928 212-980-9155
Tonix Pharmaceuticals Holding Corp. (Filer) CIK: 0001430306 (see all company filings)

EIN.: 261434750 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36019 | Film No.: 251113771
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)